Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (1296)	1/3/2000 9:43:00 PM
From: JF Quinnelly	Read Replies (1) \| Respond to of 3202

Up 49%, to 89? I must be dreaming. Rocketman, thank you thank you thank you. Your great posts gave me the confidence to hang on when it looked pretty bleak.

To: LLCF who wrote (1296)	1/4/2000 5:17:00 AM
From: Doc Bones	Respond to of 3202

When I checked on the competition around midday, HGSI and AFFX were both at $157 and change. INCY has about the same number of shares issued as those two - maybe AB thinks they should all be equal - at $157. <g> Amen on Rocketman. INCY can really use a good publicist - their own PR seems to sadly lag behind the powerhouse machines of their peers, led by the day's other big gainer in genomics - CLA. wired.com HGSI & Haseltine are featured in the January Wired on life extension thru stem cells and a few other tricks. Even before the upcoming vanquishing of death, there will be miraculous benefits: Breast augmentations will come from stem cells directed with chemical signals and grown in an artificial framework. No more "rock-hard-boob syndrome, but nice, soft, fleshy boobs," says William Haseltine. Again, Amen. Doc